Yarrow Bioscience exchanges shares for pre-funded warrants; warrant count dwarfs common shares

VYNE Therapeutics Inc.

Exchanged 133,290 common shares for pre-funded warrants to purchase same number at $0.0001/share.
After exchange: 2,669,788 common shares outstanding; 25,914,530 pre-funded warrants outstanding.
Warrants immediately exercisable, subject to 9.99% beneficial ownership limitation (can be increased to 19.99%).
Exchange closed July 29, 2026; issued under Section 3(a)(9) exemption from registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.